FDAnews
www.fdanews.com/articles/177152-marinus-pharmaceuticals-ganaxolone-flops-in-pivotal-study

Marinus Pharmaceuticals’ Ganaxolone Flops in Pivotal Study

June 17, 2016

Marinus Pharmaceuticals’ ganaxolone flopped in a Phase 3 trial testing the efficacy of the candidate in adults with focal onset seizures.

Because the study failed to meet its primary endpoint, the company is ditching its efforts in this therapeutic area and instead will concentrate on evaluating the drug in status epilepticus and pediatric orphan indications.

Although the candidate missed its primary endpoint of percent change in the seizure frequency from baseline, the safety profile of ganaxolone was consistent with previous studies, the company said. Ganaxolone is the only product in Marinus’ pipeline.

View today's stories